Case Law
Shine Lawyers lead Johnson & Johnson talcum powder class action in Australia
Shine Lawyers advances class action as Johnson & Johnson settles suits for US$5.5bn
While the settlement in the United States may bring some optimism to those affected, it is essential to note that the outcomes for Australians could differ significantly. Shine Lawyers has continued to advance its class action against Johnson & Johnson in Australia, despite the recent agreement to settle ongoing lawsuits in the US for US$5.5bn. The firm filed a statement of claim on 23 July, and the initial case management conference is set for 26 August.
The class action alleges that Johnson & Johnson's talcum powder products were defective, unfit for purpose, and not of merchantable quality because they could cause cancers of the female reproductive system, epithelial tissue, or mesothelioma. The claim covers individuals with biological female sex characteristics who were diagnosed with a gynaecological cancer or mesothelioma before 1 December 2025, as well as their executors, administrators, beneficiaries, or trustees if they died before that date.
The class action focuses on specific products, including Johnson & Johnson's talcum powder. The Associated Press reported that in line with the proposed settlement, the company will issue an initial payout not exceeding US$3bn next year, with subsequent payments due in 2028. However, the settlement is contingent on the participation of at least 95% of remaining claimants.
Practitioners should monitor this case closely as it may have significant implications for class actions and product liability claims in Australia. The outcome of this matter will likely be influenced by the US settlements and the Australian court's interpretation of the relevant laws and regulations. Attorneys representing clients with similar claims should be prepared to adapt their strategies accordingly.
Craig Allsopp, head of class actions at Shine, has warned Australians to 'manage expectations regarding any potential compensation outcomes in Australia.' This cautionary note highlights the importance of understanding the unique legal landscape in each jurisdiction and the potential differences in outcomes. Practitioners should be aware that the US settlements do not necessarily guarantee similar results in Australian courts.
The class action is brought against Johnson & Johnson and its related subsidiaries in the Supreme Court of Victoria, alleging that their talcum powder products were defective and caused harm to individuals with biological female sex characteristics. The claim covers a range of cancers, including gynaecological cancers and mesothelioma. The court's decision will likely be influenced by the US settlements and the Australian court's interpretation of the relevant laws and regulations.
Practitioners should note that the class action is ongoing, and the outcome is not yet reported. However, the recent developments in the US may have significant implications for the case in Australia. Attorneys representing clients with similar claims should be prepared to adapt their strategies accordingly.